Lipocine announces financial results for the third quarter ended september 30, 2024

Salt lake city , nov. 7, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter and nine months ended september 30, 2024 and provided a corporate update. neuroactive steroids lpcn 1154, oral brexanolone, is being developed as a treatment for postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking